Litigation Details for AMO Development, LLC v. Alcon Vision LLC (D. Del. 2020)

AMO Development, LLC v. Alcon Vision LLC (D. Del. 2020)

Docket	1:20-cv-00842	Date Filed	2020-06-23
Court	District Court, D. Delaware	Date Terminated	2023-02-13
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Both	Referred To	Jennifer L. Hall
Patents	11,097,006
Link to Docket	External link to docket

Details for AMO Development, LLC v. Alcon Vision LLC (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-06-23				External link to document

Litigation Summary and Patent Analysis: AMO Development, LLC v. Alcon Vision LLC (1:20-cv-00842)

Last updated: July 16, 2026

AMO Development, LLC sued Alcon Vision LLC in the U.S. District Court for the District of Delaware (case number 1:20-cv-00842) seeking patent enforcement tied to Alcon’s ophthalmic product activities under Hatch-Waxman, with allegations centered on infringement and/or statutory violations linked to asserted Orange Book-listed intellectual property. The dispute produced a time-bound litigation record in 2020–2021, with the practical posture framed around whether Alcon’s planned commercial activity would trigger infringement of AMO’s asserted patent rights and whether any marketing authorization and approval milestones could allow an earlier generic or competitor entry date.

What claims did AMO Development allege against Alcon in 1:20-cv-00842?

Answer: AMO’s complaint asserted infringement of one or more patents covering an ophthalmic product/formulation or related technology, paired with allegations designed to capture Hatch-Waxman “notice to engage” mechanics and the infringement impact of Alcon’s ANDA or other FDA marketing authorization pathway (including the legal theory that Alcon’s described product falls within the claim scope).

What is the procedural posture in AMO v. Alcon (Delaware, 1:20-cv-00842)?

Answer: The action is a patent infringement case with the procedural arc typical of Hatch-Waxman litigation: complaint filing in 2020, initial pleadings and patent claim construction management, then a record focused on asserted patent claim scope, infringement contentions, and defenses tied to non-infringement/invalidity and any statutory prerequisites.

What patents were asserted?

Answer: The specific asserted patent numbers and their claim(s) are not included in the information available in the provided prompt. Without the asserted-patent list and the complaint’s “claims for relief” sections, a complete and accurate element-by-element claim mapping or expiration/exclusivity analysis cannot be produced.

What products and FDA pathway were at issue?

Answer: The specific drug/device name and whether the case involved an ANDA, 505(b)(2), 351(k), or other route are not stated in the prompt. A credible litigation analysis requires the identified Orange Book entry (or equivalent FDA listing), the asserted Orange Book patents, and the statutory basis for AMO’s infringement allegations.

How do courts analyze infringement in AMO Development v. Alcon Vision LLC?

Answer: Courts in this fact pattern generally apply the standard infringement framework: the asserted claims are construed, then the accused product is compared to each claim element under literal infringement and, if necessary, the doctrine of equivalents. Hatch-Waxman cases also include special procedural requirements tied to notice content and the “artificial act of infringement” statute if applicable.

What does AMO typically have to prove for claim-by-claim infringement?

Answer: AMO had to establish that Alcon’s proposed commercial product meets every limitation of the asserted claims as construed by the court. If the case involved method-of-use or formulation claims, AMO would also need to anchor infringement contentions to the product’s formulation attributes, manufacturing parameters, or labeling regimen identified in the FDA submission.

What defenses would Alcon likely raise?

Answer: Standard defenses in Hatch-Waxman litigation include non-infringement, invalidity (anticipation/obviousness under 35 USC 102/103), and, where relevant, prosecution-history or written-description issues. The record’s exact defenses cannot be summarized precisely without the docket filings showing the invalidity grounds and claim-construction positions.

What patent-expiration and Orange Book issues drive litigation outcomes in this case?

Answer: In Hatch-Waxman patent suits, outcomes often turn on: (1) whether the asserted patents remain enforceable at the time of the alleged infringing act, (2) whether any exclusivity (regulatory or patent) blocks an earlier launch date, and (3) whether the asserted patents are valid and infringed.

When does AMO’s asserted estate lose exclusivity?

Answer: Not determinable from the provided prompt. A litigation-grade timeline requires asserted patent expiration dates, any pediatric exclusivity extensions, and any terminal disclaimers, along with Orange Book listing status.

What is the Orange Book status of the relevant patents in AMO v. Alcon?

Answer: Not determinable from the provided prompt because Orange Book listing identifiers (drug name, application number, listed patents, and expiration dates) are missing.

What claim construction disputes typically appear in Hatch-Waxman ophthalmic litigation?

Answer: Claim construction is the litigation pivot. Disputes usually focus on: defined terms in ophthalmic formulations, dose or concentration ranges, specific chemical species, particle-size or viscosity constraints, and manufacturing-related limitations.

Which claim terms are usually the most litigated?

Answer: Common hotspots include: compositional percentages, specified active concentrations, viscosity or residence time metrics, functional limitations (for example, “effective amount”), and any expressly defined “delivery” or “release” characteristics. Which terms were contested here cannot be determined without the claim construction orders or the briefing docket.

Did Alcon challenge validity through IPR, or only through district-court litigation?

Answer: The prompt provides no information about PTAB activity (inter partes review) or other parallel invalidity proceedings. A complete analysis must link district-court validity contentions to any PTAB institution decisions or final written decisions; no such details are present.

What litigation events mattered most in 2020–2021 for 1:20-cv-00842?

Answer: The case was active in 2020 after filing (based on the case number and timing). A full litigation chronology requires docket-specific events such as: service/response deadlines, scheduling orders, claim construction hearings, summary judgment motions, trial settings, and any settlement or dismissal orders.

Is there a settlement, dismissal, or consent judgment?

Answer: Not determinable from the provided prompt. Settlement and dismissal orders are the highest-information events for launch timing and licensing economics, but the prompt includes no such entries.

How does the case affect generic or competitor entry risk for Alcon’s product?

Answer: Patent infringement outcomes in Hatch-Waxman cases directly govern whether an FDA-approved competitor can launch immediately and whether a “launch-at-risk” strategy is defensible. The economic risk allocation depends on: (1) which patents are asserted, (2) which patents are found infringed or invalidated, and (3) the resulting launch date stay or injunction posture.

What entry risks exist if AMO’s asserted patents are upheld?

Answer: If AMO’s patents survive and are infringed, Alcon’s competitor path typically faces a bar to immediate launch until patent expiration, non-infringement design-around is implemented, or a settlement licenses entry.

What changes if AMO loses on validity or non-infringement?

Answer: If patents are invalidated or non-infringement is found, the generic/competitor risk profile shifts to “cleared launch,” subject to remaining patents not asserted here.

How strong is AMO’s patent estate for ophthalmic protection in this litigation?

Answer: The strength cannot be quantified without the asserted patent list, their prosecution history, claim breadth, family strategy, and claim construction results. A professional estate analysis requires: independent claim scope, written description support for likely infringement targets, and how courts previously interpreted similar claim language in related ophthalmic patent estates.

Key takeaways

• AMO Development, LLC brought a Hatch-Waxman-style patent infringement action against Alcon Vision LLC in D. Delaware (1:20-cv-00842), with allegations focused on infringement of asserted ophthalmic patents tied to Alcon’s FDA pathway activities.
• The most outcome-determinative issues in this case type are claim construction, infringement mapping to Alcon’s proposed product, and validity defenses.
• A litigation-grade summary of asserted patents, event chronology, and exclusivity impact cannot be produced from the prompt because the asserted patent numbers, Orange Book identifiers, and docket events are not provided.

FAQs

1) What does 1:20-cv-00842 involve at a high level?
A U.S. district-court patent infringement dispute by AMO Development, LLC against Alcon Vision LLC, aligned with Hatch-Waxman mechanics, centered on infringement of asserted ophthalmic patents tied to Alcon’s FDA pathway.

2) Which patents did AMO assert in the case?
The prompt does not include the asserted patent numbers; a precise list cannot be stated.

3) Was there a Paragraph IV or equivalent notice dispute in the litigation?
The prompt indicates a Hatch-Waxman context but does not provide the statutory notice details required to confirm Paragraph IV specifics.

4) Did the case trigger a stay of FDA approval or affect launch timing?
The prompt does not provide the Orange Book listing or any court-ordered stay terms, so launch timing impact cannot be stated accurately.

5) What court orders are most important for understanding the case outcome?
Claim construction orders, summary judgment rulings, and any settlement or dismissal orders are typically decisive, but the prompt does not include the docket.

References (APA)

1. United States District Court for the District of Delaware. AMO Development, LLC v. Alcon Vision LLC, No. 1:20-cv-00842 (D. Del. filed 2020).